Salix and its lead drug Xifaxan have Valeant sniffing around a deal

Will a buyer scoop up Salix ($SLXP) and its gastrointestinal portfolio soon? Valeant Pharmaceuticals ($VRX) is reportedly eyeing a bid for the troubled drugmaker, which last year confessed to an inventory snafu that overstated its sales. The cash-rich Shire ($SHPG) is also on the hunt. Sterne Agee analyts figure a buyer with GI drugs of its own--like Shire--could afford a bid at least 20% higher than Salix's standalone value of $145. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.